Australia markets closed
  • ALL ORDS

    7,266.30
    +151.80 (+2.13%)
     
  • ASX 200

    6,988.10
    +149.80 (+2.19%)
     
  • AUD/USD

    0.7002
    -0.0031 (-0.44%)
     
  • OIL

    87.29
    +0.68 (+0.79%)
     
  • GOLD

    1,792.90
    -2.10 (-0.12%)
     
  • BTC-AUD

    52,268.62
    -253.29 (-0.48%)
     
  • CMC Crypto 200

    829.07
    +9.56 (+1.17%)
     
  • AUD/EUR

    0.6287
    -0.0021 (-0.33%)
     
  • AUD/NZD

    1.0676
    -0.0005 (-0.05%)
     
  • NZX 50

    11,852.15
    -198.17 (-1.64%)
     
  • NASDAQ

    14,003.11
    -169.65 (-1.20%)
     
  • FTSE

    7,492.45
    -61.86 (-0.82%)
     
  • Dow Jones

    34,160.78
    -7.31 (-0.02%)
     
  • DAX

    15,319.50
    -204.77 (-1.32%)
     
  • Hang Seng

    23,550.08
    -256.92 (-1.08%)
     
  • NIKKEI 225

    26,717.34
    +547.04 (+2.09%)
     

Dillard's Stock Tumbles After UBS Sees 44% Downside

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • DDS

By Sam Boughedda

Investing.com — Fashion retailer Dillard's (NYSE:DDS) has seen its shares fall in reaction to the news that UBS has initiated the stock with a sell rating, setting a price target 44% below the current share price.

Analyst Mauricio Serna set the price target at $190 after Dillard's shares finished Monday at $339.92. Heading into Tuesday's close, they are currently trading around the $275.64 mark, down around 19%.

"We think the market underestimates the pressure on DDS earnings due to tough FY22 compares and macro headwinds," said Serna.

The analyst said that Dillard's, one of the largest U.S. department stores, will continue losing market share against other retailers, with 2021 marking an earnings peak and Serna forecasting a 22% drop in the EPS compound annual growth rate over the next four years.

"Our FY22 EPS estimate is -28% below consensus. We expect EPS misses post FY21 will weigh on sentiment," explained the analyst.

Related Articles

Dillard's Stock Tumbles After UBS Sees 44% Downside

U.S. FDA panel narrowly backs Merck's at-home COVID-19 pill

Shell Deer Park Texas refinery sale delayed pending CFIUS approval - company

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting